Mechanism of Action
Dual Peptidase Inhibition
Sialorphin inhibits neprilysin (NEP/CD10) and aminopeptidase N (APN/CD13), the two primary peptidases responsible for degrading enkephalins in the synapse. By blocking enkephalin breakdown, sialorphin extends the half-life and bioavailability of endogenous Met-enkephalin and Leu-enkephalin, enhancing activation of mu and delta opioid receptors by these endogenous ligands.
Indirect Opioid Amplification
Unlike direct opioid agonists, sialorphin does not bind opioid receptors itself. Its analgesic effects require intact endogenous opioid tone and are partially blocked by naloxone. This indirect mechanism may produce analgesia with reduced tolerance and dependence risk compared to direct opioid receptor agonists, as the response is limited by the amount of endogenous opioids released.
Research Summary
Analgesia in Rodent Models
PreclinicalSubcutaneous sialorphin produces dose-dependent analgesia in rat models of inflammatory (formalin) and neuropathic pain. Analgesic potency is comparable to morphine at equimolar doses in some models. Importantly, repeated sialorphin administration does not produce the same degree of tolerance as morphine, consistent with an indirect mechanism that depends on variable endogenous opioid release.
Sexual Behavior and Hormonal Regulation
PreclinicalSialorphin is regulated by androgens in rat submandibular glands and is secreted into saliva during copulatory behavior. Its role as an endogenous opioid amplifier during sexual activity suggests it participates in pain attenuation and reward modulation associated with reproductive behavior.
Calculate your Sialorphin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Analgesia (rodent) | 1-10 mg/kg SC | Single | Subcutaneous injection |
| NEP inhibition assay | 1-100 uM | Single | In vitro enzyme assay |
Preclinical only. No human trials for sialorphin; related NEP inhibitors sacubitril and racecadotril are clinically approved.
Interactions
Safety Profile
Sialorphin is an endogenous rat peptide; a human ortholog has not been fully characterized. Indirect opioid amplification may reduce tolerance, dependence, and respiratory depression risk compared to direct opioids, but this requires human clinical validation. Potential cardiovascular effects from NEP inhibition (similar to sacubitril) require evaluation.
References
- [1]Rougeot C et al. (2003). Sialorphin, a constitutive inhibitor of the neutral endopeptidase that regulates endogenous enkephalin activity, is a circulating molecule. PNAS, 100(14), 8549-8554.
- [2]Wisner A et al. (2006). Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. PNAS, 103(47), 17979-17984.